Live News EQUITY FLASH M impact Nov 17, 2026, 09:53 PM UTC Merck Discontinues Nemtabrutinib Program After Phase 3 Safety Review Merck said it is discontinuing its nemtabrutinib program after a Phase 3 safety review. MRK SquawkNews Desk